NVIDIA announced a major co-innovation AI lab partnership with Lilly on January 12, 2026, focusing on robotics and physical AI for drug discovery, while analysts maintain a Zacks Rank #1 (Strong Buy) due to expected robust earnings growth.
- Executives, including CEO Jensen Huang, sold shares under pre-set 10b5-1 plans, with Huang selling 75,000 shares for $13.75 million.
- Analysts anticipate robust earnings growth, projecting a +70.8% increase in EPS this quarter.
- The stock traded slightly lower at $183.79, reflecting a -0.58% decline in line with the broader market.